Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable ...

Apogee Therapeutics develops RORγt-targeted therapies as Nasdaq today highlights clinical-stage biotech activity.

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles properly due to suppression by the tumor.

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

Two phase 3 trials for clascoterone have shown significant improvements in patients’ hair counts. One study showed a ...

The Warburg effect describes how cancer cells switch from oxidative phosphorylation to glycolysis even in oxygen-rich ...

In the expanding field of peptide-based research, a combination of two bioactive molecules—BPC‑157 and TB‑500—has garnered ...

Tesamorelin is a synthetic 44–amino acid analog of growth hormone–releasing hormone (GHRH) that has attracted attention outside the experimental domain for its potential as a research tool. This ...

BeOne Medicines, a global oncology company, today announced that Health Canada has granted a Notice of Compliance (NOC), ...